Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
November 13, 2020 16:05 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials
November 10, 2020 16:05 ET | Phathom Pharmaceuticals
Pivotal Phase 3 PHALCON-EE trial enrollment expected to complete before year-end 2020; top-line results expected in the second half of 2021Pivotal Phase 3 PHALCON-HP trial enrollment expected to...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
September 09, 2020 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals Reports Second Quarter 2020 Results
August 06, 2020 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
July 13, 2020 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals Provides Clinical Trial Status Update
June 15, 2020 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals to Present at Upcoming Investor Conferences
May 28, 2020 16:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Pharmaceuticals Reports First Quarter 2020 Results
May 12, 2020 08:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference
April 09, 2020 16:30 ET | Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom-Logo-RGB-300dpi-01.png
Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates
March 19, 2020 08:30 ET | Phathom Pharmaceuticals
Successfully Finished 2019 with Initiation of Two Pivotal Phase 3 Trials for Vonoprazan in Erosive Esophagitis (PHALCON-EE) and H. pylori Infection (PHALCON-HP) and Completion of $209M Initial Public...